![natus discount natus discount](https://i.pinimg.com/originals/fa/ce/64/face646aba183efebfc76269f39a5a5a.jpg)
with and into Natus Medical Incorporated, and may not contain all of the information that is important to you. This summary highlights selected information from this proxy statement related to the merger (the “Merger”) of Prince Mergerco Inc. Accordingly, you are cordially invited to attend a special meeting of stockholders of the Company (the “Company Stockholder Meeting”) to be held via a virtual meeting on, 2022, at Eastern Time in order to vote on a proposal to adopt the Merger Agreement. We refer to this transaction as the “Merger.” We cannot complete the Merger until our stockholders have adopted the Merger Agreement and we have obtained necessary regulatory approvals. Under the terms of the Merger Agreement, Merger Sub will be merged into Natus, each outstanding share of our common stock (other than shares, if any, owned directly or indirectly by Parent or Merger Sub) will be cancelled and converted into the right to receive $33.50 in cash (without interest and less any applicable withholding taxes) and Natus will become a privately held subsidiary of Parent. (“Merger Sub”), which are legal entities formed by funds managed by ArchiMed to facilitate its acquisition of Natus. Zimmer Biomet loses appeal on $3.On April 17, 2022, your Board of Directors approved an Agreement and Plan of Merger (as amended from time to time, the “Merger Agreement”) by and among Natus Medical Incorporated (“Natus,” the “Company,” “we,” “us,” or “our”), Prince Parent Inc.Invacare fires President and CEO Matthew Monaghan.Össur acquires finger prosthetics company Naked Prosthetics.Study says Abbott’s HeartMate3 heart pump extends survival by 5 years.FDA clears Neuronetics’ motor threshold detection tech.Galaxy Medical wins CE mark for pulsed electric field system for treating AFib.
![natus discount natus discount](https://ae01.alicdn.com/kf/HTB1nCMynNSYBuNjSsphq6zGvVXaM/natus-vincere-mouse-pad-gamer-900x300mm-notbook-mouse-mat-large-gaming-mousepad-Gorgeous-pad-mouse-PC.jpg)
Intera Oncology has a serious infusion pump recall.CereVasc completes first eShunt procedure in U.S.
#Natus discount trial#
Medtronic implantable cardioverter defibrillator meets trial endpoints.Second Sight Medical merges with Nano Precision Medical, rebrands as Vivani Medical.FDA approves ‘first-in-market’ autoinjector for treating prolonged seizures.Philips Respironics has a new serious recall for certain ventilators.Report: BD’s Bard unit to pay $4.8M in hernia mesh lawsuit.Hamilton Medical’s ventilator recall is Class I.“Austin’s leadership at Natus has been vital to our advancement as a leading Neuroscience company and I am pleased to partner with him in this next phase of our growth,” Sullivan said.įiled Under: Business/Financial News, Diagnostics, Featured, Mergers & Acquisitions, Neurological, News Well, Patient Monitoring Tagged With: ArchiMed Group, Natus Medical Noll’s promotion follows what the company described as an “exemplary career” across the space of 10 years of leadership at Natus. Noll III was promoted to president of the company. In conjunction with the closing of the acquisition by ArchiMed, Natus Chief Commercial Officer Austin F. “Our Natus teammates are excited to advance the standard of care and improve outcomes and quality of life for patients affected by disorders of the brain, neural pathways, and eight sensory nervous systems as a part of ArchiMed.”ĪrchiMed Partner Justin Bateman added that the company, together with management, will “significantly expand the reach and breadth of Natus’ market leading products,” while also focusing research and development and pursuing acquisitions of “complementary businesses.” “ArchiMed’s mix of operational, medical, scientific and financial expertise will help us continue our mission to serve our customers as we internationalize and grow our business,” Natus CEO Thomas J. Under the terms of the acquisition, Natus shareholders received $33.50 in cash for each share of common stock, according to a news release. In April, the company announced that the MED Platform II fund of ArchiMed - an investment firm focused on the healthcare industry - would acquire Natus, a developer of medical devices for screening, diagnosing and treating disorders affecting the brain, neural pathways, and eight sensory nervous systems, for a total equity value of $1.2 billion.
![natus discount natus discount](https://cdn.shoplightspeed.com/shops/622160/files/32308249/547x396x2/natus-inc.jpg)
Natus Medical (Nasdaq:NTUS) announced today that ArchiMed’s investment firm completed its previously announced acquisition of the company.